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to 39.5% of eligible controls. Three patients died, (1 relapse, 2
infection) compared to 17 controls (9 relapse, 5 infection, 3
GvHD). Longer follow-up and immune recovery data are continu-
ing.
MSC use is feasible and safe without infusional toxicities and, as
our study seems to suggest, stabilize engraftment. Based on our
ﬁndings, where graft dysfunction, delayed hematological (immune)
recovery compromise the success of stem cell transplant outcome,
clinical randomized studies of MSCs are warranted.
Table 1 Patient characteristics and summary of results
PATIENTS
(n10)
CONTROLS
(n48)
Male:Female 6 (60%): 4 (40%) 29 (60%): 19 (40%)
Age (range) 8 years (2 – 15) 8 years (6 mo –18)
Malignant 7 (70%) 34 (70%)
Immune 2 (25%) 6 (13%)
Benign 1 (13%) 8 (17%)
Donor Male:Female 5:3 24:24
CD34 infused 31.8 (SD 3.1) 20 (SD 6.8). NS
CD3 infused 0.3 (SD 0.30) 0.68 (SD 0.7). NS
Overall survival
7/10 (70%)
FU 3-48 mo
31/48 (64%)
FU 2-6y
Days to Leukocyte
>1.0  109/l 12 (SD 1.9) 18 (SD 3.3) p0.0005
Days to Neutrophil
>0.5  109/l 13 (SD 1.5) 15 (SD 3.6) p0.14
Days to Platelets
>20  109/l 13 (SD 2.7) 21 (SD 14.7) p0.08
Days to Reticulocytes
>20 15 (SD 4.9) 35 (SD14.9) p0.04
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Seven patients, 3 leukemics, 2 patients with severe aplastic ane-
mia (SAA) and 2 SCID patients, underwent co-transplantation
with mesenchymal stem cells (MSC) and hematopoietic stem cells
(HSC). MSC were given in a pilot study to 4 patients and for graft
failure and retransplantation to 3 patients. HSCT donors were 3
HLA-identical siblings and 4 unrelated (2 matched and 1 major
mismatched unrelated and 1 mismatched unrelated cord blood).
Conditioning was myeloablative in 4 patients and RIC in 3 pa-
tients. MSC donors were HLA-identical siblings in 3 cases and
haploidentical in 4 cases. Passage 2-3 MSC were given at a dose of
1106/kg patient weight within 4 hours of the HSCT graft.
ANC 0.5109/L was reached in a median of 12 (range 10-28)
days. Platelets 30109/L was achieved in a median of 12 (8-36)
days. All patients had 100% donor chimerism for CD3, CD19 and
CD33 within 100 days. Acute GvHD grade 0-I was seen in 5
patients, two patients had grade II one proceeded to chronic
GvHD. One patient died of aspergillosis, the other patients are
alive and well.
One patient with SAA was on Cyclosporin for Henoch-Scho¨nlein
purpura since many years. This and graft failure resolved after
retransplantation of MSC  HSC.
Conclusion: MSC co-transplantation resulted in fast engraft-
ment of ANC and platelets and 100% donor chimerism, even in 3
patients regrafted for graft failure/rejection.
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Bone marrow or blood stem cell transplantation is the only cure
for 	-thalassemia major, however, despite myeloablative condi-
tioning regimens, the basic difﬁculty is a 15-30% graft failure rate
in these patients. Our hypothesis is that there may be a T-cell
dependent graft-versus-myelon effect that establishes and stabilizes
the engraftment of allogeneic blood stem cells in patients with
thalassemia major.
In a ﬁrst attempt, we assessed the CD3 chimerism early after
transplantation in a pediatric case series of six transplantations (2
related, 4 unrelated donors) transplanted from 2001 to 2004 with a
minimum follow-up period of 2 years after transplantation. The
donors were fully matched at HLA-DRB1 (high resolution) and
HLA-A and -B (low resolution). Peripheral blood CD3 chimerism
was determined at day30 (median). Chimerism of unfractionated
WBC was determined patients beginning day 13 (median) and
repeated until a stable engraftment or graft failure was achieved.
Patients (n  4) with a CD3 donor chimerism of 80% estab-
lished a long term engraftment and remained free of erythrocyte
transfusions (days 133, 775, 815, 2033). Two of these
patients developed a low total chimerism (minimum 42% on day
93, and 45% on day 42, resp.) after that a higher total donor
chimerism had been achieved (90% on day 17 and 92% on day
20, resp.). We stopped the immunosuppressive therapy in both
patients as soon as the result of the CD3 chimerism was available.
Both patients increased their total chimerism up to 98%; one
developed GvHD II° of the skin that resolved after steroid therapy
without impairment of the total chimerism.
Two patients with a CD3 donor chimerism10% lost their graft
completely, despite the fact, that one patient showed a high total
chimerism of 89% on day 6. One patient is again on the eryth-
rocyte transfusion programme, the other engrafted after re-trans-
plant from an unrelated donor.
We conclude that early determination of the CD3 chimerism
may be helpful for patient management. In addition, monitoring of
the CD3 chimerism should be included in transplant protocols for
beta-thalassemia major.
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Background
Allogeneic hematopoietic stem cell transplantation is a well es-
tablished treatment for hematological malignancies and other con-
ditions which can be associated with signiﬁcant morbidity and
mortality, particularly the development of severe acute graft-ver-
sus-host disease (GVHD). Severe steroid-refractory acute GVHD
continues to be associated with an 80-90% mortality despite the
use of many immunosuppressive agents with differing modes of
action. Mesenchymal stem cells (MSC) are rare, non-hemopoietic
cells found in the bone marrow, capable of differentiation into
bone, cartilage, muscle and fat cells. In addition to their potential
role in tissue repair, MSC have unique immunomodulatory prop-
erties. In vitro studies demonstrate they are both non-immuno-
genic and immunosuppressive. These property have been exploited
in the treatment of severe aGVHD. LeBlanc et al reported the ﬁrst
case of the successful treatment of steroid-refractory GVHD with
MSC in 2004 and in a recently reported EBMT study an overall
response rate of 69% was seen in 28 patients with steroid refractory
aGVHD. We report our experience with the use of MSC for
GVHD in 3 patients over the last 7 months.
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Cases
MSCs were cultured using a standardised protocol and reagents
in class 350 clean rooms. Doses of MSC ranged from 0.92 to
1.34  106/kg. All three recipients had received high dose steroids
prior to MSC infusions. The 1st recipient (41 yo F) received MSCs
on day55 for grade II-III skin GVHD with improvement noted
7 days later and complete resolution by day11. She is now 8
months post transplant with no conﬁrmed GVHD on minimal
immunosuppression. The 2nd recipient (31 yo M) received MSCs
on day39 and day47 for progressive grade III-IV skin, gut and
liver GVHD. ATG and etanercept were also given on day42. He
succumbed on day 54. The 3rd recipient (19 yo M) received
MSCs on day 42 for grade II-III skin GVHD with an encour-
aging initial response.
Conclusion
Preliminary studies demonstrate MSC infusion is feasible in the
treatment of steroid refractory aGVHD with encouraging initial
results. Further studies are needed to determine optimal dose,
timing and true response rate.
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Purpose: Mesenchymal stem cells (MSC) can differentiate to
several mesenchymal tissues and have been suggested to be used for
tissue repair. We explored the possibility to use MSCs to heal
chemoirradiation therapy-induced tissue toxicity.
Patients and Methods: Ten patients, median age 48 (13-64),
who had undergone allogeneic hematopoietic stem cell transplan-
tation (ASCT) were included. Seven had severe hemorrhagic cys-
titis (HC), two had pneumomediastinum and one had recurrent
perforated colon diverticulitis and peritonitis. MSC were HLA-
mismatched (n11), from haploidentical donors (n3) or siblings
(n2). Median MSC cell dose was 1.0 (range 0.7-2) x 106/kg. MSC
were infused i.v. One infusion was given to six patients, two
infusions to three and three infusions to one patient. A sensitive
nested PCR method for HLA alleles, sensitivity 10-5 - 10-6, was
used to detect residual MSC donor DNA in various tissues.
Results: Two patients with grades 4-5 HC had decreased trans-
fusion requirements after MSC infusion, but died of multi-organ
failure. In one patient, MSC donor DNA was demonstrated in the
urinary bladder. In ﬁve patients, with moderate to severe grades
2-3 HC, urine cleared after MSC infusion. In two patients, pneu-
momediastinum disappeared after MSC infusions. A patient with
steroid-resistant graft-versus-host disease of the gut experienced
perforated diverticulitis and peritonitis that was reversed twice by
MSC. Five patients died from infections and three are alive 5, 10
and 16 months after ASCT.
Conclusion: MSC is a novel therapy for therapy-induced tissue
toxicity that deserves further evaluation.
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CD4CD25 T cells (Treg) have been found to exert their affects
on multiple types of immunologically relevant cells including CD4,
CD8 and NK populations. Based upon the expanding application of
Treg cells in stem cell transplants for the control of GVHD, rejection
(HVG) and GVL responses, we hypothesized that following T cell
receptor engagement and activation in recipients, CD4CD25 cells
may modulate hematopoietic responses via production of effector
cytokines. Various populations of CD4CD25 T cells were there-
fore initially co-cultured with unfractionated syngeneic bone marrow
cells (BMC) for 24 hr. Following co-culture, cells were collected and
replated together with hematopoietic growth factors and and CFU
numbers assessed. CD4CD25 T cells were puriﬁed from BALB/c
or B6-CD8-/- mice which were then activated for 3-8 days with
anti-CD3/CD28 beads. These cells inhibited syngeneic CFU-IL3 or
CFU-HPP (multi-potential progenitors) colony formation at low
ratios of CD4CD25: BMC. Notably, Tregs from B6-CD8-/- mice
exhibited comparable inhibition of allogeneic (BALB/c) CFU-IL3.
Non-activated CD4CD25 T cells co-cultured with BMC did not
exhibit this inhibitory. Contact dependency was found to be required
for this effect as separation of activated CD4CD25 T cells from
BMC targets in trans-well cultures abrogated inhibition. Prior deple-
tion of CD25 cells in vivo resulted in increases in CFU-GM 7-9 days
after syngeneic BMT in mice suggesting that Tregs can inhibit he-
matopoietic reconstitution in vivo. TGF	 is known to inhibit prolif-
eration by hematopoietic PC. TGF	 expression was detected by
western analysis in lysates of Treg cell populations correlating with
their ability to inhibit PC responses. To examine a potential contri-
bution of TGF	 in this model, neutralizing anti-TGF	 mab was
added during Treg cell  BMC co-culture. The inhibition of CFU
activity was abrogated in the presence of this antibody. To begin
investigating the role of MHC class II molecules in this Treg cell
activity, c-kit enriched (85%) BMC from B6-MHC class II KO
and B6-wt mice were co-cultured with B6 Treg. In contrast to B6-wt
BMC, CFU inhibition was not detected against the MHC class II
deﬁcient BMC. In summary, this is the ﬁrst report demonstrating that
CD4CD25 T cells can alter hematopoietic PC activity. We hy-
pothesize that membrane bound TGF	 may participate in effecting
such regulation via direct Treg cell interactions with PC populations.
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The signiﬁcant role of direct contact between hematopoietic
progenitor cells (HPC) and the cellular microenvironment for
maintaining “stemness” has been demonstrated. Human mesen-
chymal stromal cell (MSC) feeder layers represent a surrogate
model for this interaction. To deﬁne this cell-cell contact between
HPC and MSC, we have studied adhesive interaction of various
fractions of HPC with different preparations of MSC by using a
novel assay based on gravitational force upon inversion. Adherent
and non-adherent cells were separated and further investigated by
microarray analysis (GeneChip Human Genome U133_Plus_2.0,
Affymetrix) and long-term hematopoietic culture initiating cell
(LTC-IC) frequency. HPC subsets with higher self-renewing ca-
pacity demonstrated signiﬁcantly higher adherence to MSC from
human bone marrow (CD34 vs. CD34-, CD34/CD38- vs.
CD34/CD38, slow dividing fraction vs. fast dividing fraction).
The fraction of CD34 cells that were adherent to MSC were
separated from those that were non-adherent. LTC-IC frequency
was signiﬁcantly higher in the adherent fraction. Genes coding for
adhesion proteins and extracellular matrix were higher expressed in
the adherent fraction compared to non-adherent CD34 cells.
Furthermore, afﬁnity of CD34 cells was analyzed on human
MSC isolated from bone marrow (BM), adipose tissue (AT) and
cord blood (CB). Afﬁnity to BM-MSC was signiﬁcantly higher
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